3EMS

WisdomTree Emerging Markets 3x Daily Short

ETFs & Funds · USD · LSE

3EMSETFT212

Price

$0.804

-1.29%

Cap

Earnings

30d Trend

-22.8%

3EMS
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

82% annualised over 90 days

BRAIN47 SIGNAL

0
VERY WEAK
Risk Level85
Quality50
Momentum8
Technical40
Fundamentals50

Raw weighted: 20×Macro 0.99 (1%)=20

RISK

85/100
90d Volatility
82.0%High
ATR %
6.1%High daily moves
Max Drawdown (1Y)
-75.8%Volatile

QUALITY

50/100

MOMENTUM

8/100
12-1M Momentum
-50.0%Strong downtrend
6-1M Momentum
-32.7%Negative
1M Return
-25.2%Sharp decline

TECHNICAL

40/100
RSI (14)
34.4Neutral
Price vs SMA200
-51.5%Bearish trend
MACD
+0.01Bullish momentum
Bollinger Band
14%Near lower band
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.277Noisy/choppy

FUNDAMENTALS

50/100

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 60%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months54
3-12 months20
1-5+ years39

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate WisdomTree Emerging Markets 3x Daily Short at 20/100 — a VERY WEAK reading on the Brain47 Signal. The strongest factor is quality at 50/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-25.2%

3 MONTHS

-32.4%

12 MONTHS

-75.2%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. Quality (50) and Fundamentals (50) are the primary strengths. I note that momentum is the weakest area at 8/100 — this warrants monitoring. Historical volatility is elevated at 82%. I classify this as a speculative position — elevated volatility at 82% and asymmetric payoff potential define the opportunity.

speculativeScore: 20/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.